The currently available therapies for Alzheimer’s disease (AD) include the use of cholinesterase inhibitors (donepezil, galantamine, and rivastigmine) that partially compensate the pathological reduction in acetylcholine and an NMDA receptor antagonist (memantine) that prevents the effect of the increased glutamate levels in the synaptic cleft [1]. Here, BCHE is linked to Alzheimer disease.